Merck Out-Licenses Gene Therapy Assets To FKD Therapies
Finland's FKD Therapies set up to exploit Merck & Co's gene therapy assets, and expects to start Phase II trials of a bladder cancer therapeutic in 2012.
Finland's FKD Therapies set up to exploit Merck & Co's gene therapy assets, and expects to start Phase II trials of a bladder cancer therapeutic in 2012.